NEJM: Tocilizumab is used for the treatment of hospitalized patients with neo-coronary pneumonia.

Inflammation played an important role in the pathology of Coronary Viral Disease (Covid-19) in 2019, especially in severely hospitalized patients, and researchers recently examined the efficacy of lecytocyte-6-6 blockers in patients who were hospitalized without mechanical flux treatment.
This study was a randomized, double-blind, placebo-controlled trial involving patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with at least two symptoms: fever (body temperature of 38 degrees C), lung immersion, or the need for oxygen supplementation to maintain oxygen saturation of more than 92%.
patients receive a single dose of Tocilizumab (8 mg per kilogram of body weight) or a placebo on the basis of standard care.
result of this study was intring or death, the secondary outcome was clinical deterioration and the cessation of oxygen absorption in baseline oxygen therapy patients.
243 patients were studied, 141 (58 percent) were men, the middle age was 59.8 years old, and 45 percent were Hispanic or Latino.
the risk of intestion or death in the Tocilizumab group was 0.83 compared to the placebo group, and the risk of disease worsening was 1.11.
on the 14th day, 18 percent of patients in the Tocilizumab group and 14 percent in the placebo group worsened.
the tocilizumab group stopped taking oxygen for 5.0 days and the placebo group for 4.9 days.
14 days, 24.6 percent of patients in the Tocilizumab group and 21.2 percent in the placebo group were still receiving oxygen.
risk of serious infection was lower in patients in the Tocilizumab group.
that Tocilizumab treatment does not reduce the risk of intestor or death in patients with neo-coronary pneumonia.
.